MPM Capital - Powering Breakthroughs in Life Sciences Investor Login Home Companies Team Contact Press SEARCH MPM Focus Area Drugs for the treatmentof human viral andother infectious diseasesWatch Now Chris Bardon, MD Oncology Impact Fund, Discuss Advances in Cancer Therapies Bloomberg Capital Markets, June 2016 Related Investment: Pharmasset Companies MPM Investment Strategy MPM Capital works with leading scientists to create companies that seek to address unmet needs and change the face of medicine across all therapeutic areas. MPM is currently investing out of BV2014, its most recent venture fund. In 2015 MPM partnered with UBS to create the UBS Oncology Impact Fund (OIF), an innovative impact investing fund focused exclusively on oncology that will invest in both private and public equities. OIF will support both basic cancer research as well as access to cancer care in developing countries. Fund All BV2014 Oncology Impact Fund Investments Current Exited Exit Type All IPO M A Focus Area All Oncology Other 23andMe Genetic reports for consumers to better appreciate their ancestry Other Current 28-7 Small-molecule therapeutics that modulate miRNAs for treatment Oncology Current Affymax, Inc. Previously committed to developing novel drugs Other Exited Aires Clinical stage pharmaceutical company for pulmonary disorders Other Exited Alinea Pharmaceuticals, Inc. Previously developed new treatments for metabolic conditions Other Exited Allozyne, Inc. Cancer and inflammatory disease therapeutic company Oncology Exited Alnara Orally-delivered protein therapeutics to treat metabolic diseases Other Exited Amphivena Developing bispecific TandAbs as a novel immunotherapy for hematological disorders Oncology Current Anthera Developing drugs for autoimmune diseases Other Exited Aratana Provides innovative therapies for companion animals Other Current Archus Orthopedics, Inc. Previously developed implants to treat spine disorders Other Exited ARYx Therapeutics, Inc. Previously focused on molecular design Other Exited Astute Medical Improving the diagnosis of high-risk medical conditions Other Current Atopix Therapeutics, Inc. Developing novel treatments for asthma Other Current Barrier Therapeutics, Inc. Specialized in dermatological creams and gels Other Exited BioMarin Innovative therapeutics to patients with serious unmet medical needs Other Exited Blade Therapeutics A discovery stage company focused on developing fibrosis treatments Other Current Celladon Developing a transformative therapy for heart failure Other Exited Cellerant Therapeutics, Inc. novel immunotherapies for oncology and blood-related disorders Oncology Exited Cerecor Inc. Developing innovative treatments for patients with CNS disorders Other Exited Ceregene, Inc. Development and manufacturing of gene therapies Other Exited Cerimon Pharmaceuticals, Inc. Developed and commercialized therapeutics for autoimmune diseases Other Exited CHF Solutions, Inc. Manufactures medical devices for cardiac care. Other Exited Chiasma Developing oral drugs that were previously only available by injection Other Current Clinical ink Modernize clinical trials with eSource patient engagement tools Other Current Conatus Developing novel therapeutics for liver diseases Other Exited CoStim Developing novel antibodies for cancer immunotherapy Oncology Exited CoTherix, Inc. Licensing of therapeutic products for cardiopulmonary diseases Other Exited DigiTx Partners Digital health investment partnership with Astellas Pharma Other Current Dragonfly Sciences, Inc. developing a new class of biosimilar products Other Exited EKR Therapeutics Provides acute-care specialty products Other Exited Elixir Pharmaceuticals, Inc. Develops novel pharmaceuticals for the treatment of metabolic diseases Other Exited EndoGastric Solutions, Inc. Endoluminal treatment of gastroesophageal reflux disease Other Exited Endologix Provides optimal solutions for endovascular aortic repair Other Current EnteroMedics, Inc. developer of vBloc® neurometabolic therapy Other Current Epizyme Personalized therapeutics for patients with genetically defined cancer Oncology Current ForteBio Develops analytical systems that enable real-time analysis of biomolecular interactions Other Exited Harpoon Therapeutics T cell redirection to deliver deep remissions Oncology Current Helicos Biosciences Corporation Genetic analysis for the research, drug discovery and diagnostics Other Exited Hypnion, Inc. development of novel therapeutics for (CNS) disorders Other Exited Iconic Developing therapeutics for serious eye disorders Other Current Idenix Discovers and develops drugs for human viral diseases Other Exited IDUN Pharmaceuticals, Inc. Other Exited Innovative Spinal Technologies, Inc. Developed treatments for spinal disorders Other Exited Intercell AG Modern prophylactic and therapeutic vaccines Other Exited Intracel Holdings Corporation Development and commercialization of cancer vaccines Other Exited IOmx Therapeutics AG Targeting T cell evasion to treat cancer Oncology Current iPierian Developing anti-Tau protein antibodies for neurodegenerative disease Other Exited KaloBios Pharmaceuticals, Inc. developing monoclonal antibodies for cancer care Oncology Exited MacroGenics, Inc. Oncology Exited Memory Pharmaceuticals Corp. Developed drug candidates for the treatment of CNS disorders Other Exited Meritage Pharma Treatment for eosinophilic esophagitis (EoE) Other Exited Mitobridge Discovers and develops novel drugs that enhance mitochondrial function Other Current Motus Therapeutics, Inc. Developing therapies for severe gastric mobility disorders Other Current Neosil Manufactures dermatology-focused specialty pharmaceutical products Other Exited NeoVista, Inc. Technologies for age related mucular degeneration Other Exited NeuroMed Pharmaceuticals, Inc. Produces pain therapies in the US Other Exited Nevro Developing a high-frequency stimulation technology for chronic pain Other Exited Oncorus Developing a next-generation immunotherapy platform to treat cancer Oncology Current Oxagen Limited A privately-held biopharmaceutical company Other Current Pacira Acute care products including EXPAREL for post-surgical analgesia Other Exited Peptimmune, Inc. Designs peptides for therapeutics, diagnostic kits antibodies Other Exited Pernix Therapeutics, Inc. Specialty, primary care and generic medicines Other Exited Pharmasset Discovering and developing novel drugs to treat viral infections Other Exited PharmAthene, Inc. Acquire and develop products identified as urgent priorities Other Exited Poniard Pharmaceuticals, Inc. Discovery, development and commercialization of oncology products Other Exited Portola Pharmaceuticals, Inc. A biopharmaceutical company in the hematologic diseases fields Other Exited Potenza Therapeutics Developing novel immunotherapies for the treatment of cancer Oncology Current Proteon Therapeutics Developing a therapy to improve dialysis vascular access Other Current QuatRx Pharmaceuticals Company Treatment of moderate to severe dyspareunia FDA approved in Feb 2013 Other Exited Radius Health Novel, differentiated therapeutics for patients with osteoporosis Other Current Raze Therapeutics Developing novel anti-tumor agents through mitochondrial one-carbon me Oncology Current Rhythm Developing peptide therapeutics for metabolic diseases Other Current Rigel Pharmaceuticals, Inc. Small-molecule development for inflammatory and autoimmune diseases Oncology Exited Rinat Neuroscience Corp. Develops treatment of diseases and disorders of the nervous system Other Exited SAI Drug discovery, development, and manufacturing services Other Exited Selexys Developing novel products to treat inflammatory diseases Other Current Semma Therapeutics Developing cell-based transformative therapies for diabetes patients Other Current Sideris Pharmaceuticals, Inc. Development of new treatments for transfusion related iron overload Other Exited Solasia Developing, commercializing oncology oncology supportive care drugs Oncology Current Somaxon Pharmaceuticals, Inc. Developed Silenor for treatment of insomnia Other Exited Surface Logix, Inc. Enhancing molecular functionality of pharmaceuticals Other Exited Syndax Developing and commercializing epigenetic therapies for cancer Oncology Current TCR2 Therapeutics Focused on engineering T cells for cancer therapy Oncology Current Tercica, Inc. Developed Increlex for treatment of primary IGF-1 deficiency Other Exited Tetherex Pharmaceuticals Corporation Operates in the healthcare industry focusing on biotechnology business Other Current Theraclone Sciences, Inc. Screening technology for antibodies that ward off disease Other Exited Tizona Therapeutics, Inc. Regulatory T cell suppression as a novel approach to fighting cancer Oncology Current TriNetX Platform to improve clinical research, study design recruitment Other Current True North Therapeutics Developing drugs which selectively inhibit the complement system Other Current Vaccinogen, Inc. Personalized vaccines to fight disease Oncology Other Current Valeritas Marketing a disposable insulin delivery device Other Current Vascular Developing a novel antibody for diabetic nephropathy Other Current Verastem, Inc. Treating cancer by the targeted killing of cancer stem cells Oncology Exited Verus Pharmaceuticals, Inc. Pediatric-oriented specialty pharmaceutical company Other Exited Xanodyne Pharmaceuticals, Inc. Integrated specialty pharmaceutical company Other Exited MPM Team MPM's Team is comprised of innovators, entrepreneurs, executives investors Role Investment Team Medical Scientific Advisors Operations Team Location All Cambridge San Francisco Patrick Baeuerle Patrick Baeuerle, Ph.D. Managing Director Cambridge Read Bio Chris Bardon Christiana Bardon, M.D. Managing Director Cambridge Read Bio Vinay Bhaskar Vinay Bhaskar, Ph.D. Principal San Francisco Read Bio Laura Brass Laura Brass, Ph.D., M.B.A. Managing Director Cambridge Read Bio Pablo Cagnoni Pablo J. Cagnoni, M.D. Managing Director San Francisco Read Bio Lauren Cauley Lauren Cauley Chief Financial Officer Cambridge Read Bio George Daley George Daley, M.D., Ph.D. Medical and Scientific Advisory Board (MPM OIF) MSAB Read Bio Thomas Ebeling Thomas Ebeling Medical and Scientific Advisors (OIF) MSAB Read Bio Luke Evnin Luke Evnin, Ph.D. Managing Director San Francisco Read Bio Mitchell Finer Ph.D. Mitchell Finer Ph.D. Managing Director Cambridge Read Bio Todd Foley Todd Foley, M.B.A. Managing Director Cambridge Read Bio Shinichiro Fuse Shinichiro Fuse, Ph.D. Principal Cambridge Read Bio Ansbert Gadicke Ansbert Gadicke, M.D. Managing Director Cambridge Read Bio Bard Geesaman Bard Geesaman, M.D., Ph.D. Managing Director Cambridge Read Bio William Greene William Greene, M.D. Venture Partner San Francisco Read Bio Dan Hicklin Dan Hicklin, Ph.D. Managing Director Cambridge Read Bio Robert Horvitz H. Robert Horvitz, Ph.D. Medical and Scientific Advisory Board (MPM OIF) MSAB Read Bio Sebastian Meier-Ewert Sebastian Meier-Ewert, Ph.D. Venture Partner Munich Office Read Bio Briggs Morrison Briggs Morrison, M.D. Managing Director Cambridge Read Bio Vas Narasimhan Vas Narasimhan, M.D. Medical and Scientific Advisory Board (MPM) MSAB Read Bio Gary Patou Gary Patou, M.D. Managing Director San Francisco Read Bio Sarah Reed Sarah Reed Chief Operating Officer and General Counsel Cambridge Read Bio Tony Rosenberg Tony Rosenberg Managing Director Cambridge Read Bio David Ryan David P. Ryan M.D. Medical Scientific Advisor (OIF) MSAB Read Bio Jim Scopa Jim Scopa , J.D., M.B.A. Managing Director San Francisco Read Bio Kazumi Shiosaki Kazumi Shiosaki, Ph.D. Managing Director Cambridge Read Bio Greg Sieczkiewicz Greg Sieczkiewicz, J.D., Ph.D. Managing Director Chief IP Counsel Cambridge Read Bio David Stack David Stack Managing Director Cambridge Read Bio Elizabeth Stoner Elizabeth Stoner, M.D. Managing Director Cambridge Read Bio Contact Us info@mpmcapital.com Cambridge, MA 450 Kendall Street Cambridge, MA 02142 Phone | 617-425-9200 see full map / get directions San Francisco, CA 601 Gateway Boulevard Suite 350 South San Francisco, CA 94080 Phone | 650-553-3300 see full map / get directions Print Terms Of Use Disclosures 2016 September 14, 2016 Tizona Therapeutics, Inc. Appoints George Golumbeski, Ph.D., to its Board of Directors August 16, 2016 Osteoporosis, a Disease With Few Treatment Options, May Soon Have One More Read coverage in NY Times and in Press Release August 15, 2016 Aratana Secures Third FDA Approval Animal pain drug expected to be available to veterinarians in the fall of 2016 August 11, 2016 Harvard Medical School Appoints MPM Medical and Scientific Advisory Co-Chair George Daley as New Dean Read more in The Boston Globe August 10, 2016 Iconic Therapeutics Announces Final Close of Series C Financing With Additional $10 Million Investment August 1, 2016 Astellas and MPM Capital Launch DigiTx Partners July 26, 2016 MPM Portfolio Company Blade Therapeutics Featured in the San Francisco Business Times The July 19 article, Taking it personally, cuttingedge biotech snags $45 million, discusses the latest round of funding for Blade, a company focused on finding therapies for fibrotic disease, and MPM Co-Founder Luke Evnins personal commitment to the cause. July 21, 2016 Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity Significant weight loss with targeted treatment for patients with rare genetic defect in critical weight regulation pathway July 20, 2016 Former Bluebird Bio (BLUE) CSO Takes the Reins at Oncorus; Startup Launches with $57 Million Series A June 16, 2016 MPM Portfolio Company Semma Therapeutics Featured in Boston Globe Boston-area hospitals have teamed up with the Harvard Stem Cell Institute and Semma Therapeutics to make personalized cell-based therapies and organize clinical trials. June 2, 2016 Chris Bardon, Managing Director for the Oncology Impact Fund, on Bloomberg Capital Markets Discussing Advances in Cancer Therapies as the 2016 ASCO Annual Meeting Gets Underway May 27, 2016 TriNetX Enters into Collaboration with Celgene Advance Clinical Trial Design and Research for Next-Generation Medicines Planned May 18, 2016 Aratana Therapeutics Granted FDA Approval of ENTYCE® First-of-its-Kind Ghrelin Mimetic May 3, 2016 MPM Launches $471 Million Social Impact Oncology Fund April 29, 2016 UBS Cancer Fund Shows Power of Impact Investing A new oncology fund will finance academic research and access to cancer care in developing countries April 28, 2016 UBS, MPM Seek Big Impact in Cancer Drugs with $471M Fund By Marie Powers, BioWorld Today, April 28, 2016 April 27, 2016 UBS Raises Record $471 Million for Oncology Impact Fund BioSpace.com 4/27/2016 March 21, 2016 Aratana Therapeutics Granted First FDA Approval Galliprant for the Control of Pain and Inflammation Associated with Osteoarthritis in Dogs March 14, 2016 Chiasma Initiates Phase 3 Trial to Support European Registration of Octreotide Capsules for Patients with Acromegaly March 8, 2016 Tizona Therapeutics, Inc., Completes $43 Million Series B Financing March 6, 2016 Radius Health Submits New Drug Application to the U.S. Food and Drug Administration for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis March 3, 2016 Nasdaq Welcomes Syndax Parmaceuticals, Inc. to The Nasdaq Stock Market January 9, 2016 Iconic Therapeutics Closes Series C Financing 2015 October 15, 2015 Cerecor Announces Pricing of Initial Public Offering October 15, 2015 23andMe Raises $115 Million in Series E Financing October 15, 2015 Semma Therapeutics named FierceMedicalDevices 2015 Fierce 15 September 24, 2015 FDA Office of Orphan Products Development Awards Rhythm $1 Million Grant to Support Phase 2 Study of Setmelanotide in Prader-Willi Syndrome August 27, 2015 Syndax Enters Clinical Trial Collaboration in Cancer Immunotherapy Combining Entinostat and Atezolizumab August 24, 2015 Syndax Raises $80 Million in Series C Financing August 17, 2015 Rhythm Subsidiary Raises $40 Million in Oversubscribed Financing Financing to advance Rhythm Metabolic, Inc.'s setmelanotide program for rare genetic disorders of obesity August 15, 2015 Epizyme Appoints Robert Bazemore President and Chief Executive Officer July 16, 2015 Chiasma, Inc. Prices Initial Public Offering of Common Stock July 10, 2015 Taking Clinical Trials Out of the Dark Ages (Clinical Ink) June 23, 2015 Briggs W. Morrison, M.D., CEO of Syndax, Appointed Key Strategic Advisor to MPM Capital June 15, 2015 Chiasma Submits New Drug Application to U.S. FDA for Octreotide Capsules in Acromegaly Submission based on positive results from Phase 3 clinical trial June 1, 2015 K. Peter Hirth, PhD, Joins Iconic Therapeutics as Board Member and Senior Scientific Advisor May 21, 2015 MPM Capital appoints Pablo J. Cagnoni, M.D., former Onyx Pharmaceuticals President, as Managing Director and CEO of MPM immunotherapy portfolio company Vesuvius May 14, 2015 MPM closes $400 million fund May 5, 2015 23andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. With Lupus Awareness Month Underway, Study Aims to Build a 5,000-Patient Lupus Cohort to Advance Understanding of the Disease April 22, 2015 Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology Therapeutics Exclusive Collaboration Includes Option for Astellas to Acquire Potenza April 15, 2015 Novartis International Global Head M A and Licensing Anthony Rosenberg to join as Managing Director, effective April 1, 2015 - To serve as strategic advisor and on MPM portfolio boards to build leading companies - April 7, 2015 True North Therapeutics Announces $35 Million Series B Financing March 24, 2015 Biotech Startup to Fight Diabetes on the Cellular Front Semma Therapeutics seeks to turn success in stem research lab into a way to encourage insulin production March 24, 2015 Semma Therapeutics Announces $44 Million in Funding Led by MPM Capital to Develop Cell Therapy for Treating Type 1 Diabetes; Signs Agreement with Global Pharmaceutical Company March 16, 2015 Ebb Flow: Chiasmas Private Decision March 16, 2015 Chiasma Announces Mark Leuchtenberger as Chief Executive Officer Proven Business Leader to Oversee Commercialization of Octreotide Capsules March 12, 2015 23andMe to Create Therapeutics Group, Appoints Scientific Luminary, R D Executive Richard Scheller, Ph.D. to Lead Dr. Scheller Joins 23andMes Executive Leadership Team as Chief Science Officer and Head of Therapeutics March 11, 2015 MPM Capital Announces Immuno-Oncology Pioneer Patrick Baeuerle to serve as Managing Director -Top scientist and drug developer joins MPM senior team advancing breakthroughs and discoveries March 10, 2015 Radius (RDUS) Announced Today That It Has Acquired The License To Develop And Market RAD1901 In Japan Dinesh Purandare Hired (Former Sanofi (SAN.PA) Oncology Executive To The Position Of Senior Vice President (SVP) And Head Of Global Oncology At Radius ) March 6, 2015 Vascular Pharmaceuticals, Inc. Completes $9.0 Million Expansion of Series A Financing Funding to support Phase 2 clinical trial of VPI-2690B for treatment of diabetic nephropath February 27, 2015 Chiasma Announces Completion of $70 Million Series E Financing February 27, 2015 Verastem Receives Orphan Drug Designation From FDA For VS-5584 In Mesothelioma February 24, 2015 Chiasma Appoints David Stack as Chairman of the Board; John A. Scarlett, M.D. Joins Board of Directors February 20, 2015 Syndax Says Immuno-oncology Discovery Happened Instead of an IPO February 10, 2015 Chiasma Inc. Releases Newly Published Phase 3 Study Results Show Positive Outcomes For Octreotide Capsules In People With Acromegaly, A Serious Hormonal Disorder February 9, 2015 Radius, Celladon and Nevro Among Top IPOs in 2014 MPM has #1, 8 and 10 out of the top 14 January 1, 2015 Radius: The Top Performing IPO of 2014 Radius, which is developing treatments for osteoporosis, is up 364% since pricing its June 6 initial public offering at 8 2014 December 22, 2014 Radius Announces Positive Phase 3 Top-Line Results December 15, 2014 For Venture Capital, Biotech is Where Its Really At October 29, 2014 MPM Capital is Relocating to Kendall Square October 22, 2014 Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin August 4, 2014 Aratana Featured: Start-Ups Work on Biotech Drugs for Pets July 22, 2014 Cerecor Inc. Closes on Initial Tranche of US$32M Series B Financing June 17, 2014 True North snags $22M and sets course for the clinic with a rare disease drug May 19, 2014 Proteon Therapeutics Announces $45 Million of Series D Financing Company Poised to Initiate Phase 3 Trial of PRT-201 for Reduction of AVF Failure in Hemodialysis April 29, 2014 iPierian acquired by Bristol-Myers Squibb Advances discovery strategy to pursue therapeutics for genetically defined diseases April 16, 2014 Iconic Therapeutics Raises $20 Million to Advance Clinical Development of Wet AMD Program William Greene, MD, Appointed Chief Executive Officer April 14, 2014 Celladon Receives Breakthrough Therapy Designation from FDA MYDICAR is First Gene Therapy Reported to Receive Breakthrough Designation from FDAs Center for Biologics Evaluation and Research (CBER) February 18, 2014 CoStim Pharmaceuticals, Inc. Acquired by Novartis January 27, 2014 MPM Capital and Kleiner Perkins Caufield Byers top the list of investors with the most 2013 IPOs January 7, 2014 Epizyme and Celgene Advance EPZ-5676 DOT1L Inhibitor Clinical Program to Benefit Cancer Patients with Acute Leukemias, Achieving $25 Million Clinical Proof of Concept Milestone 2016 2015 2014 back to top Copyright © 2016 MPM Capital, Inc. X X X